Recordati
| Recordati SpA
|
|
|---|---|
 |
|
| legal form | Società per azioni |
| ISIN | IT0003828271 |
| founding | 1926 |
| Seat |
Milan , Italy
|
| management |
|
| Number of employees | 4,323 |
| sales | 1.48 billion euros |
| Branch | pharmacy |
| Website | www.recordati.com |
| As of December 31, 2019 | |
Recordati is an Italian pharmaceutical company based in Milan . Recordati products are sold in over 100 countries.
history
Recordati was founded in 1926 by Giovanni Recordati in Corregio in Reggio nell'Emilia as "Laboratorio Farmacologico Reggiano". In 1953 the company moved to Milan, where the company has been listed on the stock exchange since 1984. Recordati acquired Elmu Quimica Farmaceutica from Madrid (Spain) in 1992 and Almu from Murcia (Spain) in 1998 . Two French companies, Doms-Adrian and Bouchara, were acquired in 1999 and 2000, and in 2005 the "Original Products" division of Merckle GmbH (Germany) was acquired. In the same year Recordati UK Ltd. and Recordati Hellas SA founded in Greece. A new chemical-pharmaceutical factory was also opened in Cork , Ireland. In 2006 JABA Farmaceutica was bought in Portugal, in 2007 and 2008 the French-based companies Orphan Europe, or FIC and FIC-Medicale. Further acquisitions were made in 2009 with Herbacos-Bofarma in the Czech and Slovak Republic, in 2010 with ArtMed International and in 2011 with Frik Ilaç in Turkey. In 2012 Recordati acquired the rights to OTC products in Germany, Russia, Poland and Italy. In 2013, 67% of Opalia Pharma SA and 100% of Laboratorios Casen Fleet SLU were acquired, a year later another 23% of Opalia Pharma SA died in 2016, founder and CEO Giovanni Recordati. In the same year Italchimici SpA and Pro Farma AG were bought in Switzerland. In 2018, the company received a purchase offer from a consortium led by CVC for 51.8% of the company's shares at a price of 3.03 billion euros from the family holding company FIMEI SpA
Group structure
Recordati has subsidiaries in Germany , France , Greece , Great Britain , Ireland , Portugal , Spain , Switzerland and the United States , as well as sales structures in Russia and the countries of the Commonwealth of Independent States (CIS).
The main production location for the group is Milan, which covers an area of 25,000 m², has a production capacity of 40 million pharmaceutical packages per year and specializes in the manufacture and packaging of solid oral dosage forms , injectable and topical forms. Another important plant is in Campoverde di Aprilia in the province of Latina , which covers an area of 360,000 m², with further plants in Cork (Ireland) and Montluçon (France).
Presence in Germany
In Germany Recordati is represented by Recordati Pharma GmbH in Ulm, through the acquisition of the Division original products of Merckle GmbH now operating since February 2005 as a German subsidiary of the research-based Italian pharmaceutical group Recordati. Merckle Recordati sells drugs and medical products on the German market with around 190 employees in the office and in the field. Sales in 2015 amounted to approx. 97.3 million euros. The portfolio with traditional OTC products such as Rhinopront, Mirfulan, JHP Rödler, Dolobene and Flosa Balance as well as prescription products in the areas of orthopedics / rheumatism (Lipotalon, Ortoton, Sportvis and Recosyn) and inflammatory bowel diseases (Claversal, CitraFleet) is supplemented by cardiac / Circular products from Recordati research such as lercanidipine (trade names Corifeo and Zanipress) are being strengthened. By introducing further research products and expanding the fields of indication (including urology with Kentera and allergy with Rupafin ( Rupatadin )) and Urorec for BPH, the company is looking for new growth potential.
Web links
- Recordati SpA website (Italian, English)
- Recordati Pharma GmbH website
Individual evidence
- ↑ recordati.com - Board of Directors
- ↑ a b recordati.com - Annual Report 2019
- ↑ recordati.com - Markets
- ^ Recordati SpA - History. Retrieved March 27, 2018 .
- ^ Recordati News Release. (PDF) Retrieved July 3, 2018 (English).
- ↑ CVC Capital revs up rare disease ambitions with $ 3.5B Recordati buyout | FiercePharma. Retrieved July 3, 2018 .
- ↑ Reuters Editorial: MARKETS-RhinoPront manufacturer Recordati under pressure after purchase offer . In: DE . ( reuters.com [accessed July 3, 2018]).
- ↑ Merckle Recordati became Recordati Pharma. In: www.recordati.de. Retrieved November 8, 2016 .